Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT

Efficacy and Safety of Intracameral Versus Intravitreal Bevacizumab Injection as an Adjunctive Therapy Before Trabeculectomy With Mitomycin-C in Neovascular Glaucoma: A Prospective Randomized Trial

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03648814

Enrollment

Registered

2018-08-27

Start date

2018-08-01

Completion date

2026-07-01

Last updated

2025-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Neovascular, Vascular Endothelial Growth Factor Overexpression

Keywords

Neovascular glaucoma

Brief summary

To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.

Detailed description

The present study comparing the safety and efficacy of 1.25mg/0.05mL Bevacizumab injection via the intracameral route versus the intravitreal route in treating the neovascular glaucoma

Interventions

PROCEDUREIntracameral injection

A/C injection of 1.25 mg/0.05 mL bevacizumab

PROCEDUREIntravitreal injection

Vitreous injection of 1.25 mg/0.05 mL bevacizumab

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Diagnosis of neovascular glaucoma 2. The patients having IOP \> 21 mmHg, having the indication for trabeculectomy 3. The patients' age of at least 18-year-old 4. The patients having visual potential at least hand motion. 5. Present of NVI or NVA. 6. Willing and able to provide informed consent to participate in the study 7. Able to understand the purpose of the study, his/her role, and is available to return to the clinic/hospital for all required follow-up visits

Exclusion criteria

1. One eye patient 2. Patients having severe corneal edema or total hyphema obscure NVI or NVA view. 3. Cannot obtain endothelial cell count. 4. History of bevacizumab or fluorescence dye allergy. 5. Active infectious ocular disease including endophthalmitis and corneal ulcer 6. History of systemic disease including ischemic heart disease, cerebrovascular disease, end-stage renal disease, liver failure, uncontrolled hypertension 7. Has or planning to be pregnant or breastfeeding

Design outcomes

Primary

Measure	Time frame	Description
regression of nevolascularization	2 months	Amount of nevolascular of iris and angle regression

Secondary

Measure	Time frame	Description
IOP reduction	2 months	IOP reduction at 2-month visit compare to baseline
Injection complication	2 days	Hyphema, IOP spike

Countries

Thailand

Contacts

Primary ContactAssoc.Prof.Weerawat Kiddee, MD

kweerawat@hotmail.com+66874954626

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026